Odronextamab in Patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL) Grade 1-3a: Results from a Prespecified Analysis of the Pivotal Phase II Study ELM-2
Gespeichert in:
| Veröffentlicht in: | Blood 2022-11, Vol.140 (Supplement 1), p.2280-2282 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 2282 |
|---|---|
| container_issue | Supplement 1 |
| container_start_page | 2280 |
| container_title | Blood |
| container_volume | 140 |
| creator | Kim, Tae Min Taszner, Michal Cho, Seok-Goo Novelli, Silvana Le Gouill, Steven Poon, Michelle Limei Villasboas, Jose C. Champion, Rebecca Bachy, Emmanuel Guidez, Stéphanie Alonso Alonso, Aránzazu Jagadeesh, Deepa Merli, Michele Tucker, David Cai, Jingxian Leite De Oliveira, Carolina Zhu, Min Chaudhry, Aafia Mohamed, Hesham Ambati, Srikanth R. Luminari, Stefano |
| description | |
| doi_str_mv | 10.1182/blood-2022-158404 |
| format | Article |
| fullrecord | <record><control><sourceid>elsevier_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1182_blood_2022_158404</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0006497122024958</els_id><sourcerecordid>S0006497122024958</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1424-7fe947c0b9c825c82345bad8d04279ecb818e5995ef49924775d8841e1f6c9ad3</originalsourceid><addsrcrecordid>eNp9kMFuEzEURS0EEqHwAezesl2Y2I6nY8OqqpoSaVCjAOuRx35WjDxxZDuF-SD-k2nTNYuruzpXV4eQj5x94lyJ5RBTclQwIShvlGTyFVnwRijKmGCvyYIxdk2lbvlb8q6UX4xxuRLNgvx9cDkd8E81oxkgHGBrasBDLfA71D3sMJpjQbfcoc_G1pQnuNwtd1ewTjEGe4omQzeNx30aDVyuuyu4z8YhcLoyn2e8nOK85XMawcA2YzmiDT6gg5uDiVMJBZKHukfYhsdUTYTt3hSEzQa-15Ob4K77RsV78sabWPDDS1-Qn-u7H7dfafdwv7m96ajlUkjaetSytWzQVolmzko2g3HKMSlajXZQXGGjdYNeai1k2zZOKcmR-2urjVtdEH7etTmVktH3xxxGk6ees_7Jc__suX_y3J89z8yXM4PzsceAuS92NmjRhYy29i6F_9D_AOK1hWM</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Odronextamab in Patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL) Grade 1-3a: Results from a Prespecified Analysis of the Pivotal Phase II Study ELM-2</title><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><creator>Kim, Tae Min ; Taszner, Michal ; Cho, Seok-Goo ; Novelli, Silvana ; Le Gouill, Steven ; Poon, Michelle Limei ; Villasboas, Jose C. ; Champion, Rebecca ; Bachy, Emmanuel ; Guidez, Stéphanie ; Alonso Alonso, Aránzazu ; Jagadeesh, Deepa ; Merli, Michele ; Tucker, David ; Cai, Jingxian ; Leite De Oliveira, Carolina ; Zhu, Min ; Chaudhry, Aafia ; Mohamed, Hesham ; Ambati, Srikanth R. ; Luminari, Stefano</creator><creatorcontrib>Kim, Tae Min ; Taszner, Michal ; Cho, Seok-Goo ; Novelli, Silvana ; Le Gouill, Steven ; Poon, Michelle Limei ; Villasboas, Jose C. ; Champion, Rebecca ; Bachy, Emmanuel ; Guidez, Stéphanie ; Alonso Alonso, Aránzazu ; Jagadeesh, Deepa ; Merli, Michele ; Tucker, David ; Cai, Jingxian ; Leite De Oliveira, Carolina ; Zhu, Min ; Chaudhry, Aafia ; Mohamed, Hesham ; Ambati, Srikanth R. ; Luminari, Stefano</creatorcontrib><identifier>ISSN: 0006-4971</identifier><identifier>EISSN: 1528-0020</identifier><identifier>DOI: 10.1182/blood-2022-158404</identifier><language>eng</language><publisher>Elsevier Inc</publisher><ispartof>Blood, 2022-11, Vol.140 (Supplement 1), p.2280-2282</ispartof><rights>2022 The American Society of Hematology</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c1424-7fe947c0b9c825c82345bad8d04279ecb818e5995ef49924775d8841e1f6c9ad3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,781,785,27929,27930</link.rule.ids></links><search><creatorcontrib>Kim, Tae Min</creatorcontrib><creatorcontrib>Taszner, Michal</creatorcontrib><creatorcontrib>Cho, Seok-Goo</creatorcontrib><creatorcontrib>Novelli, Silvana</creatorcontrib><creatorcontrib>Le Gouill, Steven</creatorcontrib><creatorcontrib>Poon, Michelle Limei</creatorcontrib><creatorcontrib>Villasboas, Jose C.</creatorcontrib><creatorcontrib>Champion, Rebecca</creatorcontrib><creatorcontrib>Bachy, Emmanuel</creatorcontrib><creatorcontrib>Guidez, Stéphanie</creatorcontrib><creatorcontrib>Alonso Alonso, Aránzazu</creatorcontrib><creatorcontrib>Jagadeesh, Deepa</creatorcontrib><creatorcontrib>Merli, Michele</creatorcontrib><creatorcontrib>Tucker, David</creatorcontrib><creatorcontrib>Cai, Jingxian</creatorcontrib><creatorcontrib>Leite De Oliveira, Carolina</creatorcontrib><creatorcontrib>Zhu, Min</creatorcontrib><creatorcontrib>Chaudhry, Aafia</creatorcontrib><creatorcontrib>Mohamed, Hesham</creatorcontrib><creatorcontrib>Ambati, Srikanth R.</creatorcontrib><creatorcontrib>Luminari, Stefano</creatorcontrib><title>Odronextamab in Patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL) Grade 1-3a: Results from a Prespecified Analysis of the Pivotal Phase II Study ELM-2</title><title>Blood</title><issn>0006-4971</issn><issn>1528-0020</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNp9kMFuEzEURS0EEqHwAezesl2Y2I6nY8OqqpoSaVCjAOuRx35WjDxxZDuF-SD-k2nTNYuruzpXV4eQj5x94lyJ5RBTclQwIShvlGTyFVnwRijKmGCvyYIxdk2lbvlb8q6UX4xxuRLNgvx9cDkd8E81oxkgHGBrasBDLfA71D3sMJpjQbfcoc_G1pQnuNwtd1ewTjEGe4omQzeNx30aDVyuuyu4z8YhcLoyn2e8nOK85XMawcA2YzmiDT6gg5uDiVMJBZKHukfYhsdUTYTt3hSEzQa-15Ob4K77RsV78sabWPDDS1-Qn-u7H7dfafdwv7m96ajlUkjaetSytWzQVolmzko2g3HKMSlajXZQXGGjdYNeai1k2zZOKcmR-2urjVtdEH7etTmVktH3xxxGk6ees_7Jc__suX_y3J89z8yXM4PzsceAuS92NmjRhYy29i6F_9D_AOK1hWM</recordid><startdate>20221115</startdate><enddate>20221115</enddate><creator>Kim, Tae Min</creator><creator>Taszner, Michal</creator><creator>Cho, Seok-Goo</creator><creator>Novelli, Silvana</creator><creator>Le Gouill, Steven</creator><creator>Poon, Michelle Limei</creator><creator>Villasboas, Jose C.</creator><creator>Champion, Rebecca</creator><creator>Bachy, Emmanuel</creator><creator>Guidez, Stéphanie</creator><creator>Alonso Alonso, Aránzazu</creator><creator>Jagadeesh, Deepa</creator><creator>Merli, Michele</creator><creator>Tucker, David</creator><creator>Cai, Jingxian</creator><creator>Leite De Oliveira, Carolina</creator><creator>Zhu, Min</creator><creator>Chaudhry, Aafia</creator><creator>Mohamed, Hesham</creator><creator>Ambati, Srikanth R.</creator><creator>Luminari, Stefano</creator><general>Elsevier Inc</general><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>20221115</creationdate><title>Odronextamab in Patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL) Grade 1-3a: Results from a Prespecified Analysis of the Pivotal Phase II Study ELM-2</title><author>Kim, Tae Min ; Taszner, Michal ; Cho, Seok-Goo ; Novelli, Silvana ; Le Gouill, Steven ; Poon, Michelle Limei ; Villasboas, Jose C. ; Champion, Rebecca ; Bachy, Emmanuel ; Guidez, Stéphanie ; Alonso Alonso, Aránzazu ; Jagadeesh, Deepa ; Merli, Michele ; Tucker, David ; Cai, Jingxian ; Leite De Oliveira, Carolina ; Zhu, Min ; Chaudhry, Aafia ; Mohamed, Hesham ; Ambati, Srikanth R. ; Luminari, Stefano</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1424-7fe947c0b9c825c82345bad8d04279ecb818e5995ef49924775d8841e1f6c9ad3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kim, Tae Min</creatorcontrib><creatorcontrib>Taszner, Michal</creatorcontrib><creatorcontrib>Cho, Seok-Goo</creatorcontrib><creatorcontrib>Novelli, Silvana</creatorcontrib><creatorcontrib>Le Gouill, Steven</creatorcontrib><creatorcontrib>Poon, Michelle Limei</creatorcontrib><creatorcontrib>Villasboas, Jose C.</creatorcontrib><creatorcontrib>Champion, Rebecca</creatorcontrib><creatorcontrib>Bachy, Emmanuel</creatorcontrib><creatorcontrib>Guidez, Stéphanie</creatorcontrib><creatorcontrib>Alonso Alonso, Aránzazu</creatorcontrib><creatorcontrib>Jagadeesh, Deepa</creatorcontrib><creatorcontrib>Merli, Michele</creatorcontrib><creatorcontrib>Tucker, David</creatorcontrib><creatorcontrib>Cai, Jingxian</creatorcontrib><creatorcontrib>Leite De Oliveira, Carolina</creatorcontrib><creatorcontrib>Zhu, Min</creatorcontrib><creatorcontrib>Chaudhry, Aafia</creatorcontrib><creatorcontrib>Mohamed, Hesham</creatorcontrib><creatorcontrib>Ambati, Srikanth R.</creatorcontrib><creatorcontrib>Luminari, Stefano</creatorcontrib><collection>CrossRef</collection><jtitle>Blood</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kim, Tae Min</au><au>Taszner, Michal</au><au>Cho, Seok-Goo</au><au>Novelli, Silvana</au><au>Le Gouill, Steven</au><au>Poon, Michelle Limei</au><au>Villasboas, Jose C.</au><au>Champion, Rebecca</au><au>Bachy, Emmanuel</au><au>Guidez, Stéphanie</au><au>Alonso Alonso, Aránzazu</au><au>Jagadeesh, Deepa</au><au>Merli, Michele</au><au>Tucker, David</au><au>Cai, Jingxian</au><au>Leite De Oliveira, Carolina</au><au>Zhu, Min</au><au>Chaudhry, Aafia</au><au>Mohamed, Hesham</au><au>Ambati, Srikanth R.</au><au>Luminari, Stefano</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Odronextamab in Patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL) Grade 1-3a: Results from a Prespecified Analysis of the Pivotal Phase II Study ELM-2</atitle><jtitle>Blood</jtitle><date>2022-11-15</date><risdate>2022</risdate><volume>140</volume><issue>Supplement 1</issue><spage>2280</spage><epage>2282</epage><pages>2280-2282</pages><issn>0006-4971</issn><eissn>1528-0020</eissn><pub>Elsevier Inc</pub><doi>10.1182/blood-2022-158404</doi><tpages>3</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0006-4971 |
| ispartof | Blood, 2022-11, Vol.140 (Supplement 1), p.2280-2282 |
| issn | 0006-4971 1528-0020 |
| language | eng |
| recordid | cdi_crossref_primary_10_1182_blood_2022_158404 |
| source | Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection |
| title | Odronextamab in Patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL) Grade 1-3a: Results from a Prespecified Analysis of the Pivotal Phase II Study ELM-2 |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-12T09%3A21%3A10IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-elsevier_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Odronextamab%20in%20Patients%20with%20Relapsed/Refractory%20(R/R)%20Follicular%20Lymphoma%20(FL)%20Grade%201-3a:%20Results%20from%20a%20Prespecified%20Analysis%20of%20the%20Pivotal%20Phase%20II%20Study%20ELM-2&rft.jtitle=Blood&rft.au=Kim,%20Tae%20Min&rft.date=2022-11-15&rft.volume=140&rft.issue=Supplement%201&rft.spage=2280&rft.epage=2282&rft.pages=2280-2282&rft.issn=0006-4971&rft.eissn=1528-0020&rft_id=info:doi/10.1182/blood-2022-158404&rft_dat=%3Celsevier_cross%3ES0006497122024958%3C/elsevier_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rft_els_id=S0006497122024958&rfr_iscdi=true |